bupropion has been researched along with nefazodone in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (33.33) | 18.2507 |
| 2000's | 11 (33.33) | 29.6817 |
| 2010's | 11 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Preskorn, SH | 1 |
| Rothschild, AJ | 1 |
| Stoudemire, A | 1 |
| Stahl, SM | 2 |
| Segraves, RT | 1 |
| Anand, VS; Dewan, MJ | 1 |
| Greenberg, WM | 1 |
| Horst, WD; Preskorn, SH | 1 |
| Hirschfeld, RM | 1 |
| DeVane, CL; Pollock, BG | 1 |
| Court, MH; Duan, SX; Greenblatt, DJ; Hesse, LM; Shader, RI; Venkatakrishnan, K; von Moltke, LL | 1 |
| Ferguson, JM | 1 |
| Jerome, L | 1 |
| Haney, M | 1 |
| Gupta, S; Masand, PS | 1 |
| Croft, HA; Labbate, LA; Oleshansky, MA | 1 |
| Mitchell, PB | 1 |
| Baker, B; Baldini-Rossi, N; Hollander, E; Pallanti, S; Sood, E | 1 |
| Almási, J; Rihmer, Z | 1 |
| Clayton, AH; Montejo, AL | 1 |
| Bisaga, A; Cheng, WY; Horey, JT; Levin, FR; Mariani, JJ; Nunes, E; Sullivan, M | 1 |
| Khouzam, HR | 1 |
19 review(s) available for bupropion and nefazodone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine.
Topics: 1-Naphthylamine; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Drug Design; Drug Tolerance; Drugs, Investigational; Fluoxetine; Humans; Imipramine; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles; Venlafaxine Hydrochloride | 1995 |
The diagnosis and treatment of late-life depression.
Topics: Age Factors; Aged; Antidepressive Agents; Anxiety Disorders; Bupropion; Cyclohexanols; Depressive Disorder; Diagnosis, Differential; Electroconvulsive Therapy; Female; Humans; Lithium; Male; Monoamine Oxidase Inhibitors; Piperazines; Selective Serotonin Reuptake Inhibitors; Sex Factors; Trazodone; Triazoles; Venlafaxine Hydrochloride | 1996 |
New antidepressant drugs and the treatment of depression in the medically ill patient.
Topics: Adjustment Disorders; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder; Drug Interactions; Humans; Patient Care Team; Piperazines; Selective Serotonin Reuptake Inhibitors; Sick Role; Triazoles; Venlafaxine Hydrochloride | 1996 |
Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Bupropion; Cyclohexanols; Dopamine; Humans; Mianserin; Mirtazapine; Monoamine Oxidase Inhibitors; Neurotransmitter Uptake Inhibitors; Norepinephrine; Piperazines; Receptors, Neurotransmitter; Selective Serotonin Reuptake Inhibitors; Serotonin; Synaptic Transmission; Triazoles; Venlafaxine Hydrochloride | 1998 |
Antidepressant-induced sexual dysfunction.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Female; Humans; Libido; Male; Piperazines; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological; Triazoles | 1998 |
Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Bupropion; Cyclohexanols; Depressive Disorder; Drug Prescriptions; Humans; Monoamine Oxidase Inhibitors; Piperazines; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Triazoles; Venlafaxine Hydrochloride | 1998 |
Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder; Humans; Piperazines; Triazoles; Venlafaxine Hydrochloride | 1998 |
Care of the sexually active depressed patient.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Clinical Trials as Topic; Comorbidity; Depressive Disorder; Humans; Mianserin; Mirtazapine; Piperazines; Sexual Dysfunctions, Psychological; Triazoles | 1999 |
Pharmacokinetic considerations of antidepressant use in the elderly.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Generation; Biotransformation; Bupropion; Creatinine; Cyclohexanols; Depressive Disorder; Drug Administration Schedule; Female; Half-Life; Humans; Intestinal Absorption; Liver; Male; Middle Aged; Piperazines; Triazoles; Venlafaxine Hydrochloride | 1999 |
The effects of antidepressants on sexual functioning in depressed patients: a review.
Topics: Adult; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Behavior; Sexual Dysfunctions, Psychological; Sexuality; Single-Blind Method; Triazoles | 2001 |
Effects of smoked marijuana in healthy and HIV + marijuana smokers.
Topics: Bupropion; Dronabinol; Eating; HIV Seropositivity; Humans; Marijuana Smoking; Piperazines; Substance Withdrawal Syndrome; Triazoles | 2002 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mianserin; Mirtazapine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological; Triazoles; Venlafaxine Hydrochloride; Weight Gain | 2002 |
Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation.
Topics: Antidepressive Agents; Bupropion; Controlled Clinical Trials as Topic; Depressive Disorder; Doxepin; Drug Tolerance; Erectile Dysfunction; Humans; Male; Mianserin; Mirtazapine; Moclobemide; Orgasm; Piperazines; Remission, Spontaneous; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Triazoles | 2003 |
Therapeutic drug monitoring of non-tricyclic antidepressant drugs.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Cyclohexanols; Cytochrome P-450 Enzyme System; Drug Monitoring; Humans; Mianserin; Piperazines; Selective Serotonin Reuptake Inhibitors; Trazodone; Triazoles; Venlafaxine Hydrochloride | 2004 |
Pharmacological treatments of pathological gambling.
Topics: Antidepressive Agents, Second-Generation; Behavior, Addictive; Bupropion; Comorbidity; Disruptive, Impulse Control, and Conduct Disorders; Dose-Response Relationship, Drug; Fluvoxamine; Gambling; Humans; Naltrexone; Outcome Assessment, Health Care; Paroxetine; Piperazines; Research Design; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders; Triazoles | 2005 |
[Review of antidepressants from the TCAs to the third generation drugs].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Drug Combinations; Duloxetine Hydrochloride; Humans; Mianserin; Milnacipran; Mirtazapine; Monoamine Oxidase Inhibitors; Morpholines; Piperazines; Pyrimidines; Reboxetine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Trazodone; Triazoles; Venlafaxine Hydrochloride | 2004 |
Major depressive disorder, antidepressants, and sexual dysfunction.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Depressive Disorder, Major; Humans; Mianserin; Mirtazapine; Piperazines; Sexual Dysfunctions, Psychological; Triazoles | 2006 |
Psychopharmacology of chronic pain: a focus on antidepressants and atypical antipsychotics.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bupropion; Chronic Pain; Humans; Mianserin; Mirtazapine; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Thiazoles; Trazodone; Triazoles | 2016 |
1 trial(s) available for bupropion and nefazodone
| Article | Year |
|---|---|
Comparison of substance use milestones in cannabis- and cocaine-dependent patients.
Topics: Adult; Age of Onset; Amines; Antidepressive Agents, Second-Generation; Bupropion; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug Combinations; Excitatory Amino Acid Antagonists; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; Marijuana Abuse; Piperazines; Triazoles; Young Adult | 2012 |
13 other study(ies) available for bupropion and nefazodone
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Evaluating the tolerability of the newer antidepressants.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Diseases; Citalopram; Cyclohexanols; Delayed-Action Preparations; Drug Information Services; Fluvoxamine; Gastrointestinal Diseases; Guidelines as Topic; Humans; Incidence; Paroxetine; Piperazines; Placebos; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Dysfunctions, Psychological; Triazoles; United States; United States Agency for Healthcare Research and Quality; Venlafaxine Hydrochloride | 1999 |
Visual field "shimmering" associated with nefazodone.
Topics: Bupropion; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Triazoles; Vision Disorders; Visual Fields | 1999 |
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
Topics: Antibodies; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Biotransformation; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Hydroxylation; Isoenzymes; Kinetics; Microsomes, Liver; Oxidoreductases, N-Demethylating; Paroxetine; Piperazines; Sertraline; Triazoles | 2000 |
Bupropion and drug-induced parkinsonism.
Topics: Bupropion; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Humans; Male; Middle Aged; Neurologic Examination; Parkinsonian Disorders; Piperazines; Triazoles | 2001 |